Department of Psychosomatic Medicine and Psychotherapy, University Medical Centre, Hamburg-Eppendorf & Schön Clinic Hamburg Eilbek, Hamburg, Germany.
Int J Eat Disord. 2019 Feb;52(2):101-116. doi: 10.1002/eat.22975. Epub 2018 Nov 28.
We aimed to provide a comprehensive overview of the role of self-esteem in the treatment of patients with anorexia nervosa (AN). Specifically, our objectives were to investigate the differences in self-esteem between individuals with AN and healthy controls, or individuals with other eating disorders, and to examine self-esteem as an outcome, predictor, moderator, and mediator in AN treatment.
The databases PsycINFO, PSYNDEXplus, Ovid MEDLINE®, and ProQuest were searched for studies published from 1990 to 2018. To estimate aggregated effect sizes, we performed random-effects meta-analyses.
A screening of 1,596 abstracts and 203 full-texts identified 68 relevant publications. Results suggest a significantly lower global self-esteem in individuals with AN than in healthy controls (d = -1.90, p < .001). In contrast, global self-esteem of AN and bulimia nervosa (BN) patients was found to be comparable (d = 0.05, p = .529). It might be specific to AN patients that negative self-evaluations may not affect scholastic and professional abilities. Significantly moderate self-esteem increases were observed in treated AN patients at the end of treatment (d = 0.56, p < .001), short-term (d = 0.50, p < .001), and long-term (d = 0.75, p < .001) follow-up. Self-esteem did not predict end of treatment remission-or weight-related outcome and treatment dropout. However, small to moderate predictive effects were detected on short-term (r = .15, p = .007) and long-term remission or weight (r = .33, p = .017). Finally, first indications point to self-esteem as a mediator in adult AN inpatient treatment.
The review provides insights relevant for theory, research, and practice. Implications concern the overall support for transdiagnostic approaches and the recommendation to consider low initial self-esteem for decisions on after-care.
本研究旨在全面综述自尊在治疗神经性厌食症(AN)患者中的作用。具体而言,我们的目标是调查 AN 患者与健康对照组或其他进食障碍患者之间自尊的差异,以及将自尊作为 AN 治疗的结果、预测因素、调节因素和中介因素进行研究。
我们检索了 1990 年至 2018 年期间发表的研究,使用的数据库包括 PsycINFO、PSYNDEXplus、Ovid MEDLINE®和 ProQuest。为了估计综合效应大小,我们进行了随机效应荟萃分析。
通过筛选 1596 篇摘要和 203 篇全文,确定了 68 篇相关文献。结果表明,AN 患者的总体自尊明显低于健康对照组(d=-1.90,p<0.001)。相反,AN 和神经性贪食症(BN)患者的总体自尊相当(d=0.05,p=0.529)。可能是 AN 患者的特殊情况,即负面自我评价不会影响学业和职业能力。治疗结束时,治疗后的 AN 患者的自尊显著增加(d=0.56,p<0.001),短期(d=0.50,p<0.001)和长期(d=0.75,p<0.001)随访时也有显著增加。自尊既不能预测治疗结束时的缓解或与体重相关的结果,也不能预测治疗脱落。然而,在短期(r=0.15,p=0.007)和长期(r=0.33,p=0.017)缓解或体重方面,发现了较小到中等程度的预测作用。最后,初步迹象表明自尊是成人 AN 住院治疗的中介。
本综述提供了与理论、研究和实践相关的见解。这些见解涉及对跨诊断方法的总体支持,以及建议根据初始低自尊来决定后续治疗。